Society of Hematologic Oncology Eleventh Annual Meeting 2023

Society of Hematologic Oncology

• Include: 96 videos + 1 pdf, size: 18.2 GB
•  Target Audience: oncologist, hematologist
•  Sample video: contact me for sample video

 Information:

Society of Hematologic Oncology

Topics:

• Plenary Session 1 Acute Lymphoblastic Leukemia.mp4
• Plenary Session 2 Chronic Myeloid Leukemia.mp4
• Plenary Session 3 Emerging BCL 2 Inhibitors.mp4
• Session 1 Acute Lymphoblastic Leukemia Acute Leukemia of Ambiguous Lineage.mp4
• Session 1 Acute Lymphoblastic Leukemia Approach to Ph-Like ALL.mp4
• Session 1 Acute Lymphoblastic Leukemia CNS Prophylaxis in ALL.mp4
• Session 1 Acute Lymphoblastic Leukemia Menin Inhibition for KMT2A Rearranged ALL.mp4
• Session 1 Acute Lymphoblastic Leukemia Oral Abstract ALL-300 First Report of PhALLCON A Phase 3 Study Comparing Ponatinib Versus Imatinib.mp4
• Session 1 Acute Lymphoblastic Leukemia Oral Abstract ALL-363 Comparison of Treatment Outcomes in Adolescents and Young Adults.mp4
• Session 1 Acute Lymphoblastic Leukemia Ph+ ALL – Novel Therapies.mp4
• Session 1 Acute Lymphoblastic Leukemia Role of Transplant in the Era of CAR T Cells.mp4
• Session 1 Acute Lymphoblastic Leukemia Sequencing Immunotherapies in Adults With ALL.mp4
• Session 2 Myelodysplastic Neoplasms Oral Abstract MDS-044 Cancer Disparities in Survival of Patients With Hematologic Malignancies.mp4
• Session 2 Myelodysplastic Neoplasms Oral Abstract MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia.mp4
• Session 2 Myelodysplastic Neoplasms Update on CHIP and CCUS.mp4
• Session 2 Myelodysplastic Neoplasms Update on Classifications and Prognostic Models.mp4
• Session 2 Myelodysplastic Neoplasms Update on the Biology of MDS.mp4
• Session 2 Myelodysplastic Neoplasms Update on Treatment of Higher Risk MDS.mp4
• Session 2 Myelodysplastic Neoplasms Update on Treatment of Lower Risk MDS.mp4
• Session 3 Acute Myeloid Leukemia DEBATE Achieving Best Response Is Desirable Prior to Allogeneic Stem Cell Transplant.mp4
• Session 3 Acute Myeloid Leukemia DEBATE Prior Therapy Is Not Needed for Transplanting Patients With Relapsed or Refractory AML.mp4
• Session 3 Acute Myeloid Leukemia Familial Predisposition to AML Prevalence and Implications for Management.mp4
• Session 3 Acute Myeloid Leukemia Is Acute Myeloid Leukemia with Monocytic Features a Separate Entity.mp4
• Session 3 Acute Myeloid Leukemia Oral Abstract AML-112 Impact of Consolidation Chemotherapy Intensity.mp4
• Session 3 Acute Myeloid Leukemia Post-Transplant Maintenance Therapy.mp4
• Session 3 Acute Myeloid Leukemia Triplet Regimens in AML; Beyond Azacytidine Plus Venetoclax.mp4
• Session 3 Acute Myeloid Leukemia What Is the Future of Menin Inhibitors in AML.mp4
• Session 3 Acute Myeloid Leukemia What Is the Role of Quizartinib in the Current Landscape of AML Therapy.mp4
• Session 4 Chronic Myeloid Leukemia Cost Benefit Role of TKI Choice.mp4
• Session 4 Chronic Myeloid Leukemia Epigenetic Dysregulation of CML.mp4
• Session 4 Chronic Myeloid Leukemia Genomic Complexity Beyond BCR ABL1 and Its Clinical Impact.mp4
• Session 4 Chronic Myeloid Leukemia Oral Abstract CML-310 Early Cytogenetic or Molecular Landmark.mp4
• Session 4 Chronic Myeloid Leukemia Rational Choice of TKI.mp4
• Session 4 Chronic Myeloid Leukemia The New ELN Molecular Recommendations.mp4
• Session 5 Myeloproliferative Neoplasms Addressing Anemia in Myelofibrosis.mp4
• Session 5 Myeloproliferative Neoplasms Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.mp4
• Session 5 Myeloproliferative Neoplasms Managing Accelerated and Blast Phase MPN.mp4
• Session 5 Myeloproliferative Neoplasms Modern Prognostication in Classic MPNs.mp4
• Session 5 Myeloproliferative Neoplasms Novel Non-JAK Inhibitor Therapies for Myelofibrosis.mp4
• Session 5 Myeloproliferative Neoplasms Oral Abstract MPN-470 Examining Racial Disparities in Primary Myelofibrosis.mp4
• Session 6 Multiple Myeloma BCMA GPRC5D FcRH5 CARs BsAbs How to Choose.mp4
• Session 6 Multiple Myeloma CAR BsAb Toxicity Prevention, Treatment and Surveillance.mp4
• Session 6 Multiple Myeloma DEBATE Smoldering MM Time to Treat Personalized.mp4
• Session 6 Multiple Myeloma DEBATE Smoldering MM Time to Watch and Wait.mp4
• Session 6 Multiple Myeloma Frontline Treatment for High-Risk Personalized.mp4
• Session 6 Multiple Myeloma Next Generation Therapeutics Degraders and Targeted Therapy Where Will They Fit Personalized Therapy in MM.mp4
• Session 6 Multiple Myeloma Oral Abstract MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma.mp4
• Session 6 Multiple Myeloma Treatment of Frail MM Patients Personalized Care.mp4
• Session 7 Chronic Lymphocytic Leukemia Clinical Significance of MBL.mp4
• Session 7 Chronic Lymphocytic Leukemia DEBATE Stop vs Continue VenG MRD+ at 1 Year of VenG Stop Therapy and Continue VenG.mp4
• Session 7 Chronic Lymphocytic Leukemia How Biologic Markers Impact Outcomes With Novel Therapy.mp4
• Session 7 Chronic Lymphocytic Leukemia How We Developed a Curative Therapy for CLL and Stopped Using It.mp4
• Session 7 Chronic Lymphocytic Leukemia Is FD Therapy the New SOC in FL CLL.mp4
• Session 7 Chronic Lymphocytic Leukemia Oral Abstract CLL-094 Lisocabtagene Maraleucel (liso-cel) in RR Chronic Lymphocytic Leukemia.mp4
• Session 8 T-Cell Lymphoma A Multidisciplinary Approach to the Management of Mycosis Fungoides.mp4
• Session 8 T-Cell Lymphoma Managing Rare T-Cell Lymphoma Subtypes.mp4
• Session 8 T-Cell Lymphoma New Insights Into the Pathogenesis of T-Cell Lymphoma and How This May Guide Treatment.mp4
• Session 8 T-Cell Lymphoma Novel Targeted Agents in T-Cell Lymphoma.mp4
• Session 8 T-Cell Lymphoma Tailoring Therapy in PTCL.mp4
• Session 9 Indolent B-Cell Lymphoma Bispecific Antibodies or CAR T-Cells for Indolent NHL.mp4
• Session 9 Indolent B-Cell Lymphoma Novel Combinations in Indolent Lymphoma.mp4
• Session 9 Indolent B-Cell Lymphoma Oral Abstract IBCL-098 TRANSCEND FL Phase II Study Results of Lisocabtagene.mp4
• Session 9 Indolent B-Cell Lymphoma Treatment of Follicular Lymphoma, What Is the New Order.mp4
• Session 9 Indolent B-Cell Lymphoma Treatment Options for Marginal Zone Lymphoma.mp4
• Session 10 Aggressive B-Cell Lymphoma Incorporating Novel Agents in Frontline DLBCL.mp4
• Session 10 Aggressive B-Cell Lymphoma Optimizing the Use of Novel Agents in Relapsed Refractory DLBCL.mp4
• Session 10 Aggressive B-Cell Lymphoma Oral Abstract ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab.mp4
• Session 10 Aggressive B-Cell Lymphoma The Emergence of Bispecific Antibodies in Aggressive B-Cell Lymphoma.mp4
• Session 10 Aggressive B-Cell Lymphoma The New Algorithm for Second-Line LBCL.mp4
• Session 10 Aggressive B-Cell Lymphoma The Treatment of Primary and Secondary CNS Lymphoma.mp4
• Session 10 Aggressive B-Cell Lymphoma Treatment Options for Primary Mediastinal B-Cell Lymphoma.mp4
• Session 11 Mantle Cell Lymphoma CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma.mp4
• Session 11 Mantle Cell Lymphoma Emerging Novel Agents in Mantle Cell Lymphoma.mp4
• Session 11 Mantle Cell Lymphoma Is Stem Cell Transplantation Still Necessary in Frontline Mantle Cell Lymphoma.mp4
• Session 11 Mantle Cell Lymphoma What is High Risk Mantle Cell Lymphoma and How Should We Treat It.mp4
• Session 12 Hodgkin Lymphoma Oral Abstract HL-642 Does Interim PET Assessment After Two Cycles of Treatment.mp4
• Session 12 Hodgkin Lymphoma Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies.mp4
• Session 12 Hodgkin Lymphoma Treatment of HL in Older Patients.mp4
• Session 13 Cellular Therapy DEBATE Early HCT in Myeloma.mp4
• Session 13 Cellular Therapy DEBATE Late HCT in Myeloma.mp4
• Session 13 Cellular Therapy DEBATE Should Patients with AML and Active Disease be Transplanted Con.mp4
• Session 13 Cellular Therapy DEBATE Should Patients with AML and Active Disease be Transplanted Pro.mp4
• Session 13 Cellular Therapy Oral Abstract CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation.mp4
• Session 14 Next Questions Acute Lymphoblastic Leukemia.mp4
• Session 14 Next Questions Acute Myeloid Leukemia.mp4
• Session 14 Next Questions Aggressive B-Cell Lymphoma.mp4
• Session 14 Next Questions Cellular Therapy.mp4
• Session 14 Next Questions Chronic Lymphocytic Leukemia.mp4
• Session 14 Next Questions Chronic Myeloid Leukemia.mp4
• Session 14 Next Questions Hodgkin Lymphoma.mp4
• Session 14 Next Questions Indolent B-Cell Lymphoma.mp4
• Session 14 Next Questions Mantle Cell Lymphoma.mp4
• Session 14 Next Questions Multiple Myeloma.mp4
• Session 14 Next Questions Myelodysplastic Syndromes.mp4
• Session 14 Next Questions Myeloproliferative Neoplasms.mp4
• Session 14 Next Questions T-Cell Lymphoma.mp4
• SOHO2023-Program.pdf